News summaryHelus Pharma Investor RelationsNov 16, 2026, 12:00 PM
Helus Pharma announced positive Phase 3 APPROACH results for HLP003
On Nov. 16, 2026, Helus reported Phase 3 results in 222 adults with MDD: at Week 6, MADRS fell 19.5 points with HLP003 vs. 11.9 with placebo (difference −7.6; p<0.0001; effect size 0.653); at Week 12, difference was −7.0 (p<0.0001). Response at Week 6: 56.3% vs. 28.2%; remission: 50.9% vs. 18.2%. Three treatment-related serious adverse events; no new safety signals. EMBRACE topline expected 4Q 202